KIT and neoplasm: Sorafenib, a multitargeted and multikinase inhibitor, inhibits different targets like Raf serine/threonine kinase, c-Kit, platelet-derived growth factor receptor β (PDGFR-β), and VEGFR (vascular endothelial growth factor receptor) 1–3, by inhibiting the growth and proliferation of tumor cells and also suppressing tumor angiogenesis.23By downregulating Mcl-1, it induces tumor cell apoptosis.